Head and neck cancer: gene therapy approaches. Part II: genes delivered

Area of Science:

• Oncolytic virotherapy and cancer gene therapy.
• Immunotherapy and molecular oncology.

Background:

• Adenoviral vectors are being developed for enhanced specificity, durability, and potency in gene delivery.
• Gene therapy strategies aim to improve antitumour activity in head and neck squamous cell carcinoma (HNSCC).

Purpose of the Study:

• To review the safety and efficacy of adenoviral vectors in HNSCC gene therapy.
• To discuss preclinical and clinical trial results of various genes demonstrating antitumour activity.
• To highlight advancements in gene therapy for advanced HNSCC.

Main Methods:

• Review of safety data for adenoviral vectors.
• Analysis of preclinical and clinical trial outcomes for immune modulatory genes (cytokines, tumour antigens, co-stimulatory molecules).
• Evaluation of animal studies targeting cancer growth molecules (EGFR, SOD, cyclin D1, E1A, Bcl-2).

Main Results:

• Local gene therapy injections are well tolerated and induce systemic immune responses, potentially reaching metastatic sites.
• Animal studies confirm efficacy of targeting specific molecules regulating cancer growth.
• Preliminary Phase I and II trials of Adp53 and ONYX-015 show promising efficacy in advanced HNSCC.

Conclusions:

• Adenoviral gene therapy is a promising approach for HNSCC, with potential for immune enhancement and direct antitumour effects.
• Adp53 and ONYX-015 represent significant clinical advances, warranting further Phase III trials.
• Gene therapy offers a potential strategy for treating advanced HNSCC, including metastatic disease.